TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET

Company Participants

Corey Davis - LifeSci Advisors

Glenn Mattes - President, CEO & Director

Kirk Coleman - CFO, Treasurer & Secretary

Christopher Cano - COO & VP, Business Development

Bill Williams - University of Texas, Austin

Dale Christensen - Head, Clinical Development

Conference Call Participants

Jonathan Aschoff - ROTH Capital Partners

Daniel Carlson - TW Research

Yuan Zhi - B. Riley Securities

Richard Deutsch - National Securities.

Ted Ketterer - TK Associates

Operator

Good day, and welcome to the TFF Pharmaceuticals, Inc. First Quarter 2020 Earnings Conference Call. [Operator Instructions].

I would now like to turn the conference over to Corey Davis. Please go ahead.

Corey Davis

Thank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals First Quarter Financial and Business Results Conference Call. With me on the line today is Glenn Mattes, President and CEO of TFF; Kirk Coleman, Chief Financial Officer; Dr. Dale Christensen, TFF's Director of Clinical Development; Dr. Bill Williams of the University of Texas at Austin; and Chris Cano, TFF's Chief Operating Officer.

Press release announcing our first quarter results is available on the TFF Pharmaceuticals website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference both include forward-looking statements. And these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the U.S. Securities and Exchange Commission, including the Risk Factors section of our 2022 quarterly report on Form 10-Q filed with the SEC.

And now it's my pleasure to turn the call over to Mr. Glenn Mattes. Go ahead, Glenn.

Glenn Mattes

Thank you, Corey. Good afternoon, and thank you for joining us today to review the company's first quarter operations and recent highlights. During this call, I will provide an update on our overall progress then ask our Chief Financial Officer, Kirk Coleman, to review our first quarter financials.

Having announced our fourth quarter and year-end 2021 results, just a few weeks ago, we decided to provide a more focused formal commentary of our meaningful progress for this call. This will leave more time for Q&A, and please note that Chris Cano, Dale Christensen and Dr. Bill Williams are present on today's call and will participate in that session.